New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
12:55 EDTGILD, ABT, ACHNAchillion drops after competitors report promising HCV data
Achillion (ACHN), which is developing a hepatitis C virus, or HCV, treatment, is retreating after two other companies reported that their HCV treatments had performed well in tests. Gilead (GILD) reported that it did not detect HCV in the RNA of 25 HCV patients four weeks after they were treated with the company's investigational drug. Meanwhile, Abbott (ABT) said that its HCV treatment, SVR12, had produced "high sustained viral response rates" in patients. In a note to investors earlier today, Deutsche Bank analyst Alethia Young wrote that she expects Gilead to obtain 65% of the HCV market, but she predicts that Achillion will garner a 15% share. Moreover, the analyst believes that Achillion's treatment is simpler and better than that of Abbott. She thinks that the decline in Achillion's stock today is overdone, and recommends buying the shares on weakness. Similarly, Wells Fargo analyst Brian Abraham believes that Achillion's data suggests that its treatment could be as good as or better than that of Abbott’s. Achillion is well-positioned to participate in the HCV market, and today's weakness has created an attractive entry point in the stock, he wrote. In early afternoon trading, Achillion slumped $1.06, or 11.76%, to $7.91.
News For ACHN;ABT;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
10:08 EDTGILDGilead granted European Commission marketing authorization for Harvoni
Subscribe for More Information
November 17, 2014
16:00 EDTGILDOptions Update; November 17, 2014
Subscribe for More Information
11:06 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
08:16 EDTABTZoetis to purchase assets of Abbott Animal Health for about $255M
Subscribe for More Information
08:15 EDTABTZoetis to purchase assets of Abbott Animal Health for about $255M
November 14, 2014
14:53 EDTGILDCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
November 13, 2014
13:32 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
07:53 EDTGILDLeerink to hold a tour
Subscribe for More Information
05:54 EDTACHNStocks with implied volatility movement; ACHN FXY
Subscribe for More Information
November 11, 2014
16:14 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTGILDOptions Update; November 11, 2014
Subscribe for More Information
11:35 EDTGILDUBS holds a conference call with Gilead Sciences
UBS Biotech Analyst Roden, along with Dr. Bischofberger of Gilead Sciences, discuss the recently-held AASLD Meeting and the outlook of several GILD pipeline programs on a conference call to be held on November 13 at 4:30 pm.
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
05:56 EDTACHNStocks with implied volatility above IV index mean; GME ACHN
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use